Home » Stocks » SPHS

Sophiris Bio Inc. (SPHS)

Stock Price: $0.0200 USD 0.0000 (0.00%)
Updated May 7, 2021 1:08 PM EDT - Market closed
Market Cap 636,010
Revenue (ttm) n/a
Net Income (ttm) 37,000
Shares Out 34.47M
EPS (ttm) 0.00
PE Ratio 20.00
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.0200
Previous Close $0.0200
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.0161
Day's Range 0.0161 - 0.0200
Day's Volume 17,506
52-Week Range 0.0035 - 0.2500


SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), ...

1 year ago - GlobeNewsWire

About SPHS

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatm... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements